Introduction
============

Hypertensive disorders of pregnancy (HDP) are one of the major causes of maternal mortality around the world. Routine prenatal care decreases the morbidity rate of the pregnancy-specific seizure disorder, eclampsia; however, the rate of preeclampsia, a common and major complication causing significant maternal and fetal morbidity and mortality worldwide ([@b1-mmr-19-04-2463]), remains largely unchanged in China.

A great deal of effort has been directed at the identification of HDP etiology and pathogenesis; however, there is no specific biomarker or test ready for clinical use to make early diagnosis and predict severity, although there are some encouraging findings ([@b2-mmr-19-04-2463]). Based on a century of research into HDP, there is increased understanding of this disease; however, the complete etiology and pathogenesis remain unclear because the causes of HDP are not independent and specific biomarkers and methods are limited. Therefore, identifying a useful measure to make early diagnosis and estimate the severity of HDP is currently an important research hot spot in obstetrics.

Following the development of proteomics, new approaches, including comparative differential proteomics, can provide reliable data with accurate quantitation and good reproducibility. At present there are various novel differential proteomics analysis methods, among which difference gel electrophoresis (DIGE) technology is one of the most popular, as it has high-resolution, inherited from two-dimensional gel electrophoresis (2-DE), and has high reproducibility, high sensitivity, high throughput capability and high dynamic range. DIGE is a method that can label protein samples with different fluorescent dyes prior to 2-DE, and can separate up to three different protein samples at the same time in one two-dimensional gel ([@b3-mmr-19-04-2463],[@b4-mmr-19-04-2463]). The internal standard is used to match the protein patterns across gels; thus, negating the problem of inter-gel variation, a common issue with 2-DE ([@b4-mmr-19-04-2463]). Recently, this technology has exhibited important value for early diagnosis of malignant tumors, including nasopharyngeal carcinoma, breast cancer, gastric cancer, liver cancer, autoimmune disease and infectious diseases, with specificity and sensitivity up to 90% ([@b5-mmr-19-04-2463]). This technology has also been used to investigate obstetrical diseases ([@b6-mmr-19-04-2463]). Based on differential proteome analysis of fetal accessory (including placenta, membrane, umbilical cord and amniotic fluid) and maternal body fluids, including placenta, amniotic fluid, blood, cerebrospinal fluid and urine, it is possible to investigate the molecular biology of pregnancy and its complications. By comparing the differential proteome of normal pregnancy and those with obstetrical complications, certain potential specific molecular biomarkers may be identified.

Urine is the final metabolic product of blood following glomerular filtration and renal tubule resorption; thus, the change of its composition, quantity and characteristics can reflect the information of urinary system diseases, and even the metabolic condition of the whole body. Though the American College of Obstetricians and Gynecologists no longer consider proteinuria as a diagnostic criteria for preeclampsia ([@b7-mmr-19-04-2463]), the quantity and quality of the protein changes in urine may still be associated with preeclampsia; therefore, the current study aimed to determine the differences in protein content between the urine of patients with HDP and normal pregnancy using a technology platform based on DIGE, matrix assisted laser desorption ionization-time of flight/time of flight mass spectrometry (MALDI TOF/TOF) and bioinformatics analysis. Subsequently, the content changes of identified proteins in the patient urine were validated using ELISA.

Materials and methods
=====================

### Materials

Cyanine (Cy) 2, Cy3, Cy5, Tris, 3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate, tetramethylethylenediamine, dithiothreitol (DTT), EDTA, dimethylformamide, Ettan™ 2-D Quant Kit, Ettan™ 2-D Clean-up Kit were obtained from GE Healthcare (Chicago, IL, USA). Trichloroacetic acid, trifluoroacetic acid and cyano-4-hydroxycinnamic acid were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Human prostaglandin-H2 D-isomerase (L-PGDS; cat. no. RD191113100R) and perlecan (cat. no. DPSG10) ELISA kits were from BioVendor-Laboratorni Medicina A.S. (Brno, Czech Republic).

Sample preparation
==================

Urine samples were collected from 10 patients with gestational hypertension (Group G), 10 patients with mild preeclampsia (Group M), 10 patients with severe preeclampsia (Group S) and 10 normal pregnancies (Group N) admitted to the Department of Obstetrics, Shenzhen Maternity and Child Healthcare Hospital Affiliated to Southern Medical University (Shenzhen, China) between September 2013 and December 2013, (aged 26--41). Written informed consent was obtained from all study participants and ethical approval for this study was obtained from the local research ethics committee of Southern Medical University. Gestational hypertension is diagnosed by BP ≥140/90 mmHg first appearing during pregnancy and returning to normal 12 weeks postpartum without proteinuria. Mild preeclampsia is diagnosed by BP ≥140/90 mmHg after 20 gestational weeks and urinary albumin ≥0.3 g/24 h or (+). The diagnosis criteria of severe preeclampsia includes BP ≥160/110 mmHg and urinary albumin ≥5 g/24 h or (++), serum creatinine level ≥106 µmol/l, blood platelet \<100×10^9^/l, elevated lactate dehydrogenase, elevated transaminase, persistent headache or visual disorder, persistent upper abdomen discomfort and fetal growth restriction. Women with a history of hypertension, renal disease, heart disease, liver disease, diabetes, severe anemia, malignant tumor and rheumatic disease were excluded. The clinical data from these 40 cases are presented [Table I](#tI-mmr-19-04-2463){ref-type="table"}. A total of 10 urine samples were mixed into one sample separately and then ultrafiltration and centrifugation were performed to obtain the urine protein sample. Ettan™ 2-D Clean-up kit and Ettan™ 2-D Quant kit were used to purify and quantify the urine protein sample.

### Protein labeling with CyDye DIGE fluor

Urine protein samples were labeled with Cy2, Cy3 and Cy5 following dissolving in dimethylformamide. Typically, 50 µg lysate was labeled with 400 pmol Cy3 and Cy5, while the same amount of the pool standard that contained equal quantities of all the samples was labeled with Cy2, namely the internal label. Each sample was loaded on two gels labeled with Cy3 and Cy5 to achieve statistical confidence. Prior to quenching with 1 µl 10 mM lysine for 10 min on ice, the Cy dye was placed in the dark on ice for 30 min to acquire labeling reactions. These labeled samples were then combined for 2-D DIGE analysis.

### 2-DE

2-DE was performed with Ettan™ IPGPhor and Ettan™ DALT Six electrophoresis units. Prior to SDS-PAGE, each strip was equilibrated with 10 ml equilibration buffer A (6 M urea, 50 mM Tris-HCL pH 8.8, 30% glycerol, 2% SDS, 10 mg/ml DTT) on a rocking table for 15 min, followed by 10 ml equilibration of buffer B (6 M urea, 50 mM Tris-HCL pH 8.8, 30% glycerol, 2% SDS, 25 mg/ml iodoacetamide) for another 15 min. Then the trips were loaded and run on 12% acrylamide isocratic Laemmli gels with running parameter settings as constant power of 3 W per gel for 45 min, followed by 17 W per gel until the bromophenol blue dye front had run off the bottom of the gels. Then, the Typhoon 9410 imager (GE Healthcare) was used to visualize the labeled protein and match with DIGE images with DeCyder 6.5 software (GE Healthcare) to identify the spots of interest.

### MALDI TOF/TOF and protein identification

Protein spots of interest were excised using an automatic Spot picker, and then the picked spots underwent in-gel digestion, followed by analysis with ABI 4800 MALDI TOF/TOF mass spectrometry (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The mass spectral data were submitted to the SWISSPROT database ([www.uniprot.org/](www.uniprot.org/)) using Mascot software ([www.matrixscience.com](www.matrixscience.com)). The proteins with identification probabilities of \>95% given by Mascot were considered successfully identified and then received bioinformatics analysis.

### ELISA analysis

From the identified proteins, two were selected, L-PGDS and perlecan, to be analyzed by ELISA to confirm the content change in urine. Urine samples were collected from another 50 patients with gestational hypertension (Group G), 50 patients with mild preeclampsia (Group M), 50 patients with severe preeclampsia (Group S) and 50 normal pregnancies (Group N) admitted to Department of Obstetrics, Shenzhen Maternity and Child Healthcare Hospital Affiliated to Southern Medical University (Shenzhen, China), between January 2014 and December 2014. Similarly, written informed consent was obtained from all study participants and ethical approval for this study was obtained from the local research ethics committee of Shenzhen Hospital, Southern Medical University (Shenzhen, China). The inclusion criteria were consistent with the diagnosis criteria. Women with a history of hypertension, renal disease, heart disease, liver disease, diabetes, severe anemia, malignant tumor and rheumatic disease were excluded. According to the kit (BioVendor-Laboratorni Medicina A.S.), the urine concentration of L-PGDS and perlecan were determined in all patients.

### Statistical analysis

Data were presented as the mean ± standard deviation. The one-way analysis of variance and further multiple comparisons by Student-Newman-Keuls test were used for comparing the L-PGDS and perlecan between Group N, G, N and M. SPSS (version 19.0; IBM Corp., Armonk, NY, USA) was used for statistical analysis. P\<0.05 was considered to indicate the statistically significant difference.

Results
=======

### Results of 2-DE and mass spectrometry

Total proteins were extracted from the urine of 10 patients with gestational hypertension, 10 patients with mild preeclampsia, 10 patients with severe preeclampsia and 10 normal pregnancies, and then 50 µg samples of the four groups subjected to SDS-PAGE electrophoresis for accuracy ([Fig. 1](#f1-mmr-19-04-2463){ref-type="fig"}). The 2-DE images were obtained by fluorescence scanning and analyzed using DeCyder software to estimate the abundance of proteins in each sample objectively to provide quantitative data. A filter threshold of 1.5 was set to detect the protein spots of interest that had a significant change among the four groups. Compared with the normal pregnancy group, 44 differential protein spots were identified, among which 22 were upregulated and 22 were downregulated in the gestational hypertension group, 15 were upregulated and 30 downregulated in the mild preeclampsia group compared with the gestational hypertension group. There were 45 differential protein spots when comparing the severe preeclampsia group with the mild preeclampsia group, of which 9 were upregulated and 36 were downregulated. On account of some protein spots changing in all four groups, 65 differential protein spots were analyzed in total ([Fig. 2](#f2-mmr-19-04-2463){ref-type="fig"}).

Following mass spectrometry analysis, 30 differential proteins were identified. Ceruloplasmin, Ig-γ-3 chain C region and pancreatic α-amylase were all upregulated in hypertensive disorders in pregnancy; however, hemopexin, antithrombin-III, kininogen-1, α-2-HS-glycoprotein, vitamin D-binding protein, actin cytoplasmic 2, apolipoprotein A-I and chorionic somatomam-motropin hormone were all downregulated. For α-1B-glycoprotein, cadherin-11, pregnancy-specific β-1-glycoprotein 11, gelsolin, inter-α-trypsin inhibitor heavy chain H4, keratin type II cytoskeletal 2 epidermal, protein α-1-microglobulin/bikunin precursor (AMBP), vesicular integral-membrane protein VIP36, filamin-A-interacting protein 1, semenogelin-1, L-PGDS, Ig κ chain V--III region WOL, perlecan, mannan-binding lectin serine protease 2, fibrinogen alpha chain and long palate, lung and nasal epithelium carcinoma-associated protein 1 contents were higher in gestational hypertension than in normal pregnancies, but lower in mild and severe preeclampsia. By contrast, serum albumin and α-1-antitrypsin were lower in gestational hypertension compared with normal pregnancies, and higher in mild and severe preeclampsia. No significant difference was observed in the remaining protein, ganglioside GM2 activator, in the four groups. The genes and functions of all these identified proteins are presented in [Table II](#tII-mmr-19-04-2463){ref-type="table"}.

Using the DeCyder software, abundance curves of these differential protein spots, no. 1,618 and no. 1,911, which can reflect the state of renal function were simulated ([Figs. 3](#f3-mmr-19-04-2463){ref-type="fig"} and [4](#f4-mmr-19-04-2463){ref-type="fig"}). The abundance ratio of gestational hypertension and normal pregnancies for spot no. 1,618 was 2.13, and the ratio was 1.58 for spot no. 1911. However, for mild and severe preeclampsia, the abundance curve exhibited reductions in spot no. 1,618 and no. 1,911, with ratios of 0.26 and 0.16 in mild preeclampsia, respectively, and 0.06 and 0.04 in severe preeclampsia, respectively. According to mass spectrometry analysis and database searching, spot no. 1,618 was confirmed as L-PGDS and no. 1911 was perlecan. In consideration of their change trends, the two proteins may have important effects in the genesis of gestational hypertension and preeclampsia.

### Results of ELISA

To validate the results regarding L-PGDS and perlecan, ELISA was used for further confirmation in another 50 patients with gestational hypertension (Group G), 50 patients with mild preeclampsia (Group M), 50 patients with severe preeclampsia (Group S) and 50 normal pregnancies (Group N). When observing the changes in L-PGDS, there was significant difference among the four groups and further multiple comparisons indicated that there was no variation between Group N (1.26±0.25 µg/ml) and Group G (1.32±0.16 µg/ml); however, the concentration of L-PGDS in Group M (0.94±0.23 µg/ml) and Group S (0.78±0.23 µg/ml) were significantly lower than that of Group N and Group G (both P\<0.001). When comparing Group M with Group S, there were significantly lower levels in Group S (P=0.023). Regarding the urine perlecan concentration, the results illustrated a higher concentration in Group G (12.73±3.71 nmol/l; P=0.036) and lower in Group M (8.02±1.66 nmol/l, P=0.006) and Group S (6.63±1.39 nmol/l, P\<0.001) compared with Group N (9.99±1.85 nmol/l). Similarly, perlecan was decreased in Group S compared with Group M (P=0.039; [Table III](#tIII-mmr-19-04-2463){ref-type="table"}).

Discussion
==========

With the development of DIGE and MALDI TOF/TOF technologies, proteomic research has been widely used in the post-genomics era, and can provide new opportunities to identify the novel biomarkers for various important diseases, as it allows for the large-scale investigation of proteins in complex biological fluids and tissues in a high-throughput manner. The proteomic studies of preeclampsia have predominantly focused on maternal blood, placenta, amniotic fluid and trophoblast cells ([@b3-mmr-19-04-2463],[@b4-mmr-19-04-2463]). When comparing the levels the low molecular-weight protein in serum from patients with preeclampsia in the early second trimester with a control group, Anand *et al* ([@b8-mmr-19-04-2463]) identified \>60 potential biomarkers, which when modeled in a 14 different multi-marker combinations exhibited sensitivity and specificity of \>90% for the early detection of women at risk for preeclampsia. Another proteomic study on preeclampsia indicated that C1s subcomponent and protein AMBP were significantly overexpressed in the preeclamptic serum ([@b9-mmr-19-04-2463]), which may be useful in early prediction.

Although urine is a good source of biomarkers, there few studies have researched preeclampsia using urine samples and no consistent results have been found ([@b10-mmr-19-04-2463]). Carty *et al* ([@b11-mmr-19-04-2463]) used a proteomic strategy to identify urinary biomarkers that predict preeclampsia prior to the onset of disease and screened out several biomarkers, including fibrinogen α chain, collagen α chain and uromodulin fragments, which may contribute to better prediction, monitoring and accurate diagnosis of preeclampsia.

Proteinuria is used to distinguish between gestational hypertension and preeclampsia; therefore, the quantity and component changes of urine protein may have important role in distinction of these two types of hypertensive disorders of pregnancy ([@b12-mmr-19-04-2463],[@b13-mmr-19-04-2463]). Differential proteins were examined in the urine of patients with gestational hypertension, mild preeclampsia, severe preeclampsia and normal pregnancies using DIGE and mass spectrometry, and 30 differential proteins were identified, among which α-1B-glycoprotein, cadherin-11, pregnancy-specific β-1-glycoprotein 11, gelsolin, inter-α-trypsin inhibitor heavy chain H4, keratin type II cytoskeletal 2 epidermal, protein AMBP, vesicular integral-membrane protein VIP36, filamin-A-interacting protein 1, semenogelin-1, mannan-binding lectin serine protease 2, fibrinogen α chain and long palate, lung, nasal epithelium carcinoma-associated protein 1, Ig κ chain V--III region WOL, L-PGDS and perlecan were overexpressed in gestational hypertension, and expression was reduced in patients with mild and severe preeclampsia compared with that of normal pregnancies. All these proteins have their own functions and may have certain effects on the disease; information on their functions is presented in [Table III](#tIII-mmr-19-04-2463){ref-type="table"}.

L-PGDS (β trace protein) has anionic charge, is of smaller molecular weight than serum albumin (26,000 vs. 66,000 Da) and catalyzes prostaglandin H2 conversion into prostaglandin D2. L-PGDS is distributed in the central nervous system, visual system, male genital system and cardiovascular system. L-PGDS is synthesized in the choroid plexus or leptomeninges of the brain and secreted steadily through cerebrospinal fluid into circulating blood. Therefore it can be detected in cerebrospinal fluid, aqueous fluid, blood plasma, urine and amnio fluid. As serum L-PGDS is excreted through glomerular capillary walls, reduction in the number of functioning glomeruli decreases the renal clearance of L-PGDS and increases serum L-PGDS concentrations. Urinary L-PGDS excretions may be more useful to predict the increased glomerular permeability in an early stage of systemic diseases because of the larger molecular weight and its anionic property ([@b14-mmr-19-04-2463],[@b15-mmr-19-04-2463]). In the current study, the concentration of urinary L-PGDS was decreased in preeclampsia, particularly in severe preeclampsia, indicating that the renal function was altered in these patients. However, an opposing view can be found in which urinary L-PGDS excretions are increased in patients with various forms of renal diseases ([@b16-mmr-19-04-2463]). Therefore, in the future transgenic L-PGDS knock-out mouse models should be used to verify its function in preeclampsia. Additionally, the product produced by L-PGDS, prostaglandin D2, which inhibits platelet aggregation and causes relaxation of vascular smooth muscle, may have a role in the genesis of preeclampsia development ([@b17-mmr-19-04-2463]).

Perlecan is a basement membrane-specific heparan sulfate proteoglycan core protein and is one of the largest proteoglycans, with a protein core of \~500 kDa that can be modified by the addition of N-terminal heparan sulfate side chains. Perlecan is particularly abundant in basement membrane and pericelluar spaces, where it regulates diverse cellular processes, including bone formation, inflammation, cardiac development and angiogenesis. Located at the glomerular basement membrane and glomerular endothelial surface layer, perlecan is the major component of the filtration barrier and has an important role in maintaining renal function. The N-terminal heparan sulfate side chains of perlecan act as a reservoir for growth factors, which can promote angiogenesis by presenting growth factors to their respective cell surface receptors ([@b18-mmr-19-04-2463],[@b19-mmr-19-04-2463]). By contrast, perlecan can inhibit the autophagy of cells ([@b18-mmr-19-04-2463]). The result of the current study demonstrated that perlecan was decreased in the urine of patients with preeclampsia compared with normal pregnancies, and may indicate the existence of glomerular filtration barrier injury resulting in proteinuria and renal dysfunction, which supports previous research ([@b20-mmr-19-04-2463]). The downregulated expression perlecan in renal organ of different renal diseases and models explains the pathogenesis of renal injury caused not only by glomerular filtration barrier injury but also by the decrease of angiogenesis and the increase of autophagy accompanied the decrease of perlecan. All these evidence supported that perlecan may have effect in the renal change of preeclampsia. Future work will likely ensure this effect using gene knock-out model.

In conclusion, compared with normal pregnancies, differential proteins were identified in the urine of patients with gestational hypertension and preeclampsia. The identified proteins may be good biomarkers for predicting and diagnosing the hypertensive disorders in early pregnancy. L-PGDS and perlecan may be involved in the genesis and development of renal injury in preeclampsia. Further studies will be performed to investigate the function of L-PGDS and perlecan in preeclampsia.
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###### 

Patient clinical information.

  Characteristic           Group N        Group G        Group M        Group S        F-value   P-value
  ------------------------ -------------- -------------- -------------- -------------- --------- ---------
  Age (years)              32.58±4.43     33.41±4.56     31.72±5.12     34.02±3.96     0.243       0.865
  Gravity                  2.38±1.27      2.58±1.13      2.43±1.21      2.41±1.34      0.026       0.994
  Parity                   0.68±0.26      0.75±0.17      0.73±0.21      0.67±0.25      0.147     0.93
  Gestational age (days)   277.75±18.27   274.36±20.15   269.56±22.35   265.84±20.75   0.329       0.804

Group N, normal pregnancies; Group G, gestational hypertension; Group M, mild preeclampsia; Group S, severe preeclampsia.

###### 

Functional analysis of differential proteins.

  Accession no.   Protein name                                                           Gene name   Functions
  --------------- ---------------------------------------------------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  P00450          Ceruloplasmin                                                          CP          Transfer Fe2+ into Fe3+, play an important role in the iron transport in the membrane
  P02768          Serum albumin                                                          ALB         Regulate the osmotic pressure of the blood
  P04217          α-1B-glycoprotein                                                      A1BG        Play a role in the regulation of Cell recognition and cellular behaviour
  P01009          α-1-antitrypsin                                                        SERPINA1    Irreversible inhibition of trypsin, chymotrypsin and fibrinolysin
  P02790          Hemopexin                                                              HPX         Combine and transport heme
  P55287          Cadherin-11                                                            CDH11       A kind of Calcium-depend cell protein and can differentiate Heterogeneous cells
  P01008          Antithrombin-III                                                       SERPINC1    The most important serine protease inhibitor in plasma
  P01042          Kininogen-1                                                            KNG1        Play role in blood clotting, inhibit platelet aggregation and increase blood vessel permeability
  P02765          α-2-HS-glycoprotein                                                    AHSG        Stimulate the endothocytic effect of cells and affect bone formation
  P01860          Ig-γ-3 chain C region                                                  IGHG3       Participate in the immune system
  P04746          Pancreatic α-amylase                                                   AMY2A       One kind of digestive enzyme
  P02774          Vitamin D-binding protein                                              GC          A multifunctional protein that carries vitamin D and inhibits actin polymerization
  Q9UQ72          Pregnancy-specific β-1-glycoprotein 11                                 PSG11       A specific protein involved in the pregnancy process that play role in the foetal chromosomal abnormalities prenatal diagnosis and foetal growth restriction
  P06396          Gelsolin                                                               GSN         A calcium-regulated actin, acting in the process of cilia formation
  P63261          Actin, cytoplasmic 2                                                   ACTG1       A class of highly conserved proteins present in a variety of motor cells
  Q14624          Inter-α-trypsin inhibitor heavy chain H4                               ITIH4       Acting in the acute response period
  P35908          Keratin, type II cytoskeletal 2 epidermal                              KRT2        Involved in the keratinization process, and keratinocyte activation, value-added
  P02760          Protein AMBP                                                           AMBP        Include three fragments: a1 microglobulin, a trypsin inhibitor light chain and trypstatin
  Q12907          Vesicular integral-membrane protein VIP36                              LMAN2       Play role of intracellular lectin in the early secretion and involved in transporting polymer galactose
  Q7Z7B0          Filamin-A-interacting protein 1                                        FILIP1      Involved in the role of silk protein-A/F-actin axis, control of new cortical cells from the beginning of the ventricle area
  P04279          Semenogelin-1                                                          SEMG1       Involved in the formation and ejaculation of gel matrix in epididymal secretions
  P41222          Prostaglandin-H2 D-isomerase                                           PTGDS       Catalyses the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation, and an inhibitor of platelet aggregation
  P01623          Ig κ chain V--III region WOL                                           --          Part of immunoglobulin, involving in the immune system
  P02647          Apolipoprotein A-I                                                     APOA1       Involved in the reverse transport of cholesterol from the tissue to the liver
  P01243          Chorionic somatomam-motropin hormone                                   CSH1        Participate in stimulating lactation, foetal growth and metabolism in pregnancy
  P98160          Basement membrane specific heparan sulfate proteoglycan core protein   HSPG2       The complete composition of the basement membrane, as a matrix appendage of cells, plays an important role in vascularization
  P17900          Ganglioside GM2 activator                                              GM2A        Can regulate phospholipid single chain and fatty acid, Can be combined with ganglioside to stimulate ganglioside GM2 degradation
  O00187          Mannan-binding lectin serine protease 2                                MASP2       Serum proteins play an important role in the activation of complement systems through mannan-binding lectin serine protease 2
  P02671          Fibrinogen α chain                                                     FGA         Fibrinogen has a dual function: the monomer polymerization into fibrin, and act as a cofactor in platelet aggregation
  Q8TDL5          Long palate, lung and nasal epithelium carcinoma-associated protein1   LPLUNC1     By identifying and removing pathogens, it may be a primary body of the human body defence mechanism

The data were obtained from the Swissprot database (<https://www.uniprot.org/>) and NCBI protein database (<http://www.ncbi.nlm.nih.gov/>).

###### 

ELISA results of L-PGDS and perlecan in the four patient groups.

  Protein             Group N                                                                                                     Group G                                                                                                     Group M                                                     Group S     F-value   P-value
  ------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------- --------- ---------
  L-PGDS (µg/ml)      1.26±0.25^[a](#tfn3-mmr-19-04-2463){ref-type="table-fn"}--[c](#tfn5-mmr-19-04-2463){ref-type="table-fn"}^   1.32±0.16^[b](#tfn4-mmr-19-04-2463){ref-type="table-fn"},[c](#tfn5-mmr-19-04-2463){ref-type="table-fn"}^    0.94±0.23^[c](#tfn5-mmr-19-04-2463){ref-type="table-fn"}^   0.78±0.23   68.59     \<0.001
  Perlecan (nmol/l)   9.99±1.85^[b](#tfn4-mmr-19-04-2463){ref-type="table-fn"}--[d](#tfn6-mmr-19-04-2463){ref-type="table-fn"}^   12.73±3.71^[b](#tfn4-mmr-19-04-2463){ref-type="table-fn"},[c](#tfn5-mmr-19-04-2463){ref-type="table-fn"}^   8.02±1.66^[c](#tfn5-mmr-19-04-2463){ref-type="table-fn"}^   6.63±1.39   64.01     \<0.001

P\>0.05 vs. Group G

P\<0.05 vs. Group M

P\<0.05 vs. Group S

P\<0.05 vs. Group G. Group N, normal pregnancies; Group G, gestational hypertension; Group M, mild preeclampsia; Group S, severe preeclampsia; L-PGDS, prostaglandin-H2 D-isomerase.
